---
title: "Capricor falls as FDA sets up AdCom meeting to review Duchenne therapy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290979037.md"
description: "Capricor Therapeutics (CAPR) shares fell approximately 12% after the FDA scheduled an advisory committee meeting for July 29 to review its Biologics License Application for Deramiocel, a Duchenne muscular dystrophy treatment. This follows a previous rejection in July 2025 and a resubmitted application accepted in March with a target action date of August 22."
datetime: "2026-06-26T14:15:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290979037.md)
  - [en](https://longbridge.com/en/news/290979037.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290979037.md)
---

# Capricor falls as FDA sets up AdCom meeting to review Duchenne therapy


### Related Stocks

- [CAPR.US](https://longbridge.com/en/quote/CAPR.US.md)

## Related News & Research

- [QUICK SPARK: Capricor Stock Dives — 'Complete Fraud' Says Pharma Bro Martin Shkreli](https://longbridge.com/en/news/293956617.md)
- [Capricor publishes advisory committee presentation on deramiocel clinical data in Duchenne muscular dystrophy](https://longbridge.com/en/news/293953736.md)
- [Capricor Therapeutics (CAPR) Secures New Headquarters Tied To FDA Decision On Deramiocel](https://longbridge.com/en/news/293853158.md)
- [Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel | CAPR Stock News](https://longbridge.com/en/news/293951290.md)
- [Capricor Stock Tumbles After FDA Panel Rejects Evidence for Duchenne Cell Therapy](https://longbridge.com/en/news/294379447.md)